(Q44781560)

English

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.

scientific article published on 21 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

Dietger Niederwieser

17

object named as

Dietger Niederwieser

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Wolfram Pönisch

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Simone Heyn

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Juliane Beck

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ina Wagner

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Martin Mohren

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Franz A Hoffmann

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Thoralf Lange

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Marion Schmalfeld

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Thomas Zehrfeld

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andreas Schwarzer

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Cornelia Winkelmann

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Thomas Edelmann

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ramona Röhrborn

13

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Karin Hebenstreit

14

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Haifa K Al-Ali

15

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Nadja Jäkel

16

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

21 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

162

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

202-209

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12361

21 January 2018

Identifiers

10.1111/BJH.12361

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44781560&oldid=1749500264"